Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D boosted its position in Progyny, Inc. (NASDAQ:PGNY) by 1.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,717 shares of the company’s stock after acquiring an additional 787 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.07% of Progyny worth $2,023,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Progyny by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock valued at $317,097,000 after purchasing an additional 41,687 shares in the last quarter. Jennison Associates LLC raised its stake in Progyny by 2.7% in the first quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock valued at $99,054,000 after buying an additional 67,632 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Progyny by 3.1% during the 1st quarter. Principal Financial Group Inc. now owns 1,400,701 shares of the company’s stock worth $53,437,000 after buying an additional 42,302 shares during the last quarter. Congress Asset Management Co. MA boosted its position in shares of Progyny by 11.8% during the 1st quarter. Congress Asset Management Co. MA now owns 1,009,483 shares of the company’s stock worth $38,512,000 after acquiring an additional 106,574 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Progyny by 14.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 844,679 shares of the company’s stock worth $31,406,000 after acquiring an additional 105,544 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insider Activity

In other news, Director Cheryl Scott sold 1,462 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the transaction, the director now directly owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, President Michael E. Sturmer sold 9,030 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the transaction, the president now directly owns 362,583 shares of the company’s stock, valued at approximately $10,877,490. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cheryl Scott sold 1,462 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the transaction, the director now owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.

Progyny Stock Up 1.0 %

PGNY opened at $16.62 on Friday. The business has a 50 day moving average price of $24.33 and a two-hundred day moving average price of $28.78. Progyny, Inc. has a 52 week low of $13.93 and a 52 week high of $42.08. The company has a market cap of $1.50 billion, a PE ratio of 27.25, a P/E/G ratio of 1.97 and a beta of 1.45.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. The firm had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share. As a group, sell-side analysts expect that Progyny, Inc. will post 0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PGNY shares. Canaccord Genuity Group decreased their target price on Progyny from $24.00 to $18.00 and set a “hold” rating for the company in a research note on Friday. Truist Financial lowered their target price on shares of Progyny from $33.00 to $26.00 and set a “buy” rating for the company in a report on Thursday. BTIG Research lowered shares of Progyny from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Cantor Fitzgerald cut their target price on Progyny from $37.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Progyny has an average rating of “Hold” and an average target price of $27.73.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.